{"id":"NCT01599234","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis","officialTitle":"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2005-12","completion":"2005-12","firstPosted":"2012-05-15","resultsPosted":"2012-08-16","lastUpdate":"2023-05-03"},"enrollment":337,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Sativex","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis","primaryOutcome":{"measure":"Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment)","timeFrame":"0-15 weeks","effectByArm":[{"arm":"Sativex","deltaMin":-1.22,"sd":1.76},{"arm":"Placebo","deltaMin":-0.91,"sd":1.72}],"pValues":[{"comp":"OG000 vs OG001","p":"0.220"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":23},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["20307378","25475413"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":167},"commonTop":["Fatigue","Dizziness","Nausea","Urinary Tract Infection Not Otherwise Specified","Asthenia"]}}